We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Next-Generation Gas Chromatograph and GC/MSD Enable New Levels of Performance

By LabMedica International staff writers
Posted on 12 Feb 2013
A new gas chromatograph (GC) and a mass selective detector to function with the GC offer a broad, feature-rich portfolio, and enable superior levels of sensitivity, reliability, and productivity.

Agilent Technologies (Santa Clara, CA, USA) introduces the Agilent 7890B gas chromatograph and the 5977A Series GC/MSD (mass selective detector) to offer the industry's broadest, feature-rich portfolio of superior performance GC, GC/MSD, and related software. More...
Agilent also offers factory-tested, preconfigured solutions to help fast-track setup and operation. "Customers will find significant product improvements, eco-friendly capabilities, and lower cost of ownership, along with unsurpassed performance,” said Monty Benefiel, Agilent vice president for Gas Phase Systems.

Based on the known reliability of the Agilent GC platform, the new 7890B GC is faster, easier to operate, and more cost-effective. The 7890B GC features Improved performance specifications with advances in numerous detector modules; Lower operating costs and ecofriendly operation with power/gas management and sleep/wake modes; Seamless ordering of consumables and parts with an interactive graphical Parts Finder tool and consumables database; Easier, faster method development with integrated GC calculators and wizards; Better asset and resource management with integrated maintenance tools; Improved recovery of active compounds with Agilent's exclusive end-to-end Inert Flow Path deactivation technology; Reduced downtime for MS maintenance using the new Fast Vent feature.

The Agilent 7890B GC runs on Agilent OpenLAB Chromatography Data System software. The new Agilent OpenLAB CDS is up to 40 times faster than previous versions, with a new Data Analysis package and Intelligent Reporting. Advanced interactive integration tools and graphical displays accelerate data review, reducing time-to-results and freeing up operators for other tasks. "Our customers require the means to efficiently and accurately analyze their data as well as information about their laboratory assets to support decision making or gain further scientific insight. OpenLAB does all of that," said Bruce von Herrmann, Agilent vice president for Software and Informatics. "With streamlined workflows and complete data and method migration from ChemStation and EZChrom, OpenLAB is a fully scalable solution for a single laboratory, multiple workgroups, and entire enterprises."

The Agilent 5977A Series GC/MSD provides all the benefits of the 7890B GC plus features a redesigned inert MS ion source that enhances performance with highly efficient ion collection. The 5977A Series GC/MSD now offers the highest sensitivity on the market, with a new specification metric, the Instrument Detection Limit, for system-level performance in practice. Using Agilent's TwisTorr 304 FS turbomolecular vacuum pump, optimized for light gas operation, the new 5977A GC/MSD system is efficient and rugged, and has been evaluated and certified to meet Agilent’s leading quality standards. The GC/MSD runs on Agilent MassHunter Workstation software solution for high-throughput MS data analysis, and also includes a full version of MSD ChemStation to ensure compatibility with previously purchased instruments.

Related Links:
Agilent Technologies, Inc.
Agilent 7890B GC and 5977A Series GC/MSD
Agilent Inert Flow Path Solutions



Gold Member
STI Test
Vivalytic MG, MH, UP/UU
Online QC Software
Acusera 24•7
Pipette Calibration System
Artel PCS®
Prefilled Tubes
Prefilled 5.0ml Tubes
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Characterization of EV separated by distinct methods (Photo courtesy of Yuanyuan Liu, Yanbin Guo et al. Engineering, doi.org/10.1016/j.eng.2025.12.009)

Liquid Biopsy Biomarkers May Improve Childhood Epilepsy Diagnosis

Childhood epilepsy remains a major neurological disorder with unmet needs for accurate, non-invasive biomarkers, as conventional tests such as electroencephalography and neuroimaging can have limited sensitivity... Read more

Molecular Diagnostics

view channel
Image: NeoCircle Study Synopsis (George, A.M., Chen, Y., Gladchuk, S. et al. EMBO Molecular Medicine (2026). DOI: 10.1038/s44321-026-00447-z)

Ultrasensitive MRD Blood Test Detects Early Breast Cancer Recurrence

SAGA Diagnostics (Morrisville, NC, USA), a company specializing in tumor-informed, blood-based cancer detection and precision medicine, announced the publication of a new study evaluating its Pathlight... Read more

Pathology

view channel
Image: Immune-related signals in routine bone marrow biopsy slides could help predict multiple myeloma outcomes and support more personalized treatment strategies (image credit: Shutterstock)

AI Tool Extracts Immune Signals from Biopsy to Inform Myeloma Therapy

Multiple myeloma is a bone marrow malignancy in which patients can respond very differently to the same treatments, making initial therapy decisions difficult. Clinicians must choose among options such... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.